Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 19;18:1136. doi: 10.1186/s12885-018-5031-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Case #1. (a) Chest radiography showing PD 23 months after treatment with crizotinib, with pericardial effusion and right pleural effusion. (b) Chest radiography 13 months after treatment with alectinib. Imaging revealed a moderate response in pericardial effusion and right pleural effusion. (c) MRI imaging showing PD (brain metastasis) 17 months after treatment with alectinib. (d) Graph shows the change of % G1202R mut in cfDNA using ddPCR and CEA levels during the clinical course after treatment with alectinib. % G1202R mut $= \frac{(FAM)}{(FAM + HEX)}$ ×100. PD = Progressive disease